Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors

Clin J Oncol Nurs. 2018 Oct 1;22(5):565-568. doi: 10.1188/18.CJON.565-568.

Abstract

Neuroendocrine tumors (NETs), including gastroenteropancreatic NETs, or GEP-NETs, are heterogenous tumors that arise from diffuse neuroendocrine cells and other organs, such as the lung, ovary, and thyroid. Lutetium Lu 177 dotatate (Lutathera®) is a newly approved targeted therapy for patients with advanced GEP-NETs. Patients treated with octreotide long-acting release may be candidates for this second-line therapy. This article discusses lutetium Lu 177 dotatate therapy administration and patient care considerations.

Keywords: carcinoid cancer; gastroenteropancreatic; lutetium Lu 177 dotatate; neuroendocrine tumors.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Female
  • Humans
  • Intestinal Neoplasms / drug therapy*
  • Lutetium / therapeutic use*
  • Male
  • Middle Aged
  • Neuroendocrine Tumors / drug therapy*
  • Octreotide / therapeutic use*
  • Pancreatic Neoplasms / drug therapy*
  • Radiopharmaceuticals / therapeutic use*
  • Somatostatin / therapeutic use*
  • Stomach Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents, Hormonal
  • Radiopharmaceuticals
  • Somatostatin
  • Lutetium
  • Octreotide

Supplementary concepts

  • Gastro-enteropancreatic neuroendocrine tumor